Written question asked by Robert Halfon (Conservative) on Monday, 17 October 2022, in the House of Commons. It was due for an answer on Wednesday, 19 October 2022. It was answered by Robert Jenrick (Conservative) on Tuesday, 25 October 2022 on behalf of the Department of Health and Social Care.
Voluntary Scheme for Branded Medicines Pricing and Access
- Question
-
To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme.
- Answer
-
The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.
Secondary information
- Type
- Written question
- Reference
- 64035
- Session
- 2022-23
- Subjects
- Voluntary scheme for branded medicines pricing and access
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-10-25 18:25:01 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/64035
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/64035
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/64035